News

"This is a significant milestone for our company," noted Karl Pinto, CEO of Goodwin Biotechnology. "We have been committed to investing in and advancing the field of Bioconjugation

Under the terms of a joint venture (JV) agreement between the parties, G-treeBNT will be responsible for conducting and funding all clinical trials and product development through approval

The company said that signaling components of the PI3K pathway are central regulators of cell proliferation, growth, differentiation, survival and angiogenesis. About 80% of tumor types have been

The approval is subject to certain conditions, which the two parties have agreed to undertake following completion of the proposed transaction. The three-way transaction includes GSK buying Novartis’

The API produced is expected to provide sufficient quantities of aramchol for Galmed’s potential future Phase III clinical trials of aramchol to treat Non-Alcoholic Steato-Hepatitis (NASH). As part

MN-001 exerts its effects through several mechanisms to produce its anti-fibrotic and anti-inflammatory activity in preclinical models, including leukotriene (LT) receptor antagonism, inhibition of phosphodiesterases (PDE), and inhibition

The results showed that Jakavi improved hematocrit control without the need for phlebotomy and reduced spleen size in PV patients who had an inadequate response to or unacceptable

MGD011 is a humanized CD19 x CD3 bispecific DART protein being developed to treat B-cell hematological malignancies. As part of the deal, MacroGenics will secure a $50m upfront

The company said that ENV515 is a fully biodegradable particle replication in non-wetting templates (PRINT) particle formulation of a prostaglandin analog, travoprost, with the potential for sustained intraocular